AbbVie (ABBV) stock price, revenue, and financials

AbbVie market cap is $188.6 b, and annual revenue was $33.27 b in FY 2019

$188.6 B

ABBV Mkt cap, 08-Feb-2021

$12.9 B

AbbVie Revenue Q3, 2020
AbbVie Gross profit (Q3, 2020)7.9 B
AbbVie Gross profit margin (Q3, 2020), %60.9%
AbbVie Net income (Q3, 2020)2.3 B
AbbVie EBIT (Q3, 2020)3.3 B
AbbVie Cash, 30-Sept-20207.9 B
AbbVie EV267.8 B

AbbVie Revenue

AbbVie revenue was $33.27 b in FY, 2019 which is a 1.6% year over year increase from the previous period.

Embed Graph

AbbVie Revenue Breakdown

Embed Graph

AbbVie revenue breakdown by geographic segment: 28.1% from International and 71.9% from United States

AbbVie Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

25.6b28.2b32.8b33.3b

Revenue growth, %

12%10%16%2%

Cost of goods sold

5.8b7.0b7.7b7.4b

Gross profit

19.8b21.2b25.0b25.8b

Gross profit Margin, %

77%75%76%78%

R&D expense

4.4b5.0b10.3b6.4b

General and administrative expense

5.9b6.3b7.4b6.9b

Operating expense total

10.4b11.6b18.7b13.3b

EBIT

9.4b9.6b6.4b13.0b

EBIT margin, %

37%34%19%39%

Interest expense

965.0m1.0b1.1b1.5b

Pre tax profit

7.9b7.7b5.2b8.4b

Income tax expense

1.9b2.4b(490.0m)544.0m

Net Income

6.0b5.3b5.7b7.9b

EPS

3.63.33.75.3

AbbVie Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.1b9.3b7.3b39.9b

Accounts Receivable

4.8b5.1b5.4b5.4b

Prepaid Expenses

3.6b4.7b1.9b2.4b

Inventories

1.4b1.6b1.6b1.8b

Current Assets

16.2b21.2b16.9b49.5b

PP&E

2.6b2.8b2.9b3.0b

Goodwill

15.4b15.8b15.7b15.6b

Total Assets

66.1b70.8b59.4b89.1b

Accounts Payable

9.4b10.2b1.5b11.8b

Short-term debt

402.0m6.4b5.3b3.8b

Current Liabilities

9.8b16.6b17.2b15.6b

Long-term debt

36.4b31.0b35.0b63.0b

Total Debt

36.8b37.4b40.3b66.7b

Common Stock

18.0m18.0m18.0m18.0m

Additional Paid-in Capital

13.7b14.3b14.8b15.2b

Retained Earnings

4.4b5.5b3.4b4.7b

Total Equity

4.6b5.1b(8.4b)(8.2b)

Debt to Equity Ratio

7.9 x7.3 x-4.8 x-8.2 x

Debt to Assets Ratio

0.6 x0.5 x0.7 x0.7 x

Financial Leverage

14.3 x13.9 x-7 x-10.9 x

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

4.7b6.1b8.4b9.0b3.5b8.0b4.9b5.2b10.6b41.1b6.0b7.9b

Accounts Receivable

4.7b4.9b4.9b5.8b5.8b5.8b5.7b5.5b5.5b6.4b8.4b8.4b

Prepaid Expenses

3.2b3.3b2.7b3.4b2.7b2.1b1.8b2.3b2.1b2.4b2.8b3.2b

Inventories

1.4b1.6b1.8b1.7b1.6b1.8b1.7b1.9b1.9b1.8b4.1b3.5b

Current Assets

15.5b17.0b18.9b20.4b13.8b18.5b14.4b15.1b20.2b51.8b21.3b23.0b

PP&E

2.6b2.7b2.7b2.8b2.8b3.0b2.9b2.9b2.9b3.0b4.9b5.0b

Goodwill

15.5b15.7b15.7b15.9b15.7b15.7b15.6b15.6b15.5b15.6b42.7b42.8b

Total Assets

65.7b67.0b68.8b69.3b61.6b66.2b56.8b57.1b59.4b91.2b149.5b149.6b

Accounts Payable

8.4b8.8b9.2b10.7b10.7b11.4b11.8b11.3b12.2b12.7b19.3b19.4b

Short-term debt

425.0m3.4b3.8b6.4b6.5b4.0b2.1b5.6b5.3b3.8b5.4b4.8b

Current Liabilities

8.8b12.3b13.0b17.1b17.2b15.4b13.9b16.9b17.5b16.5b24.6b24.2b

Long-term debt

36.5b33.8b34.0b30.9b30.6b36.5b35.1b31.6b33.1b63.3b82.1b82.3b

Total Debt

37.0b37.2b37.8b37.3b37.1b40.5b37.1b37.3b38.4b67.0b87.4b87.1b

Common Stock

18.0m18.0m18.0m18.0m18.0m18.0m18.0m18.0m18.0m18.0m18.0m18.0m

Additional Paid-in Capital

13.9b14.0b14.2b14.5b14.6b14.7b14.9b15.0b15.1b15.4b17.0b17.1b

Retained Earnings

5.1b6.0b6.5b5.0b5.5b6.8b4.2b3.4b3.7b6.0b3.1b3.3b

Total Equity

5.0b6.0b6.7b3.6b(3.4b)(2.9b)(7.8b)(8.6b)(8.2b)(7.4b)14.7b15.3b

Debt to Equity Ratio

7.4 x6.2 x5.7 x10.5 x-11 x-13.9 x-4.7 x-4.3 x-4.7 x-9 x5.9 x5.7 x

Debt to Assets Ratio

0.6 x0.6 x0.5 x0.5 x0.6 x0.6 x0.7 x0.7 x0.6 x0.7 x0.6 x0.6 x

Financial Leverage

13.1 x11.1 x10.3 x19.5 x-18.3 x-22.7 x-7.3 x-6.7 x-7.2 x-12.3 x10.2 x9.8 x

AbbVie Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

6.0b5.3b5.7b7.9b

Depreciation and Amortization

1.2b1.5b1.8b2.0b

Accounts Receivable

(71.0m)(391.0m)(591.0m)(74.0m)

Inventories

(38.0m)93.0m(226.0m)(231.0m)

Accounts Payable

(1.2b)425.0m190.0m(1.1b)

Cash From Operating Activities

7.0b10.0b13.4b13.3b

Purchases of PP&E

(479.0m)(529.0m)(638.0m)(552.0m)

Cash From Investing Activities

(6.1b)(274.0m)(1.0b)596.0m

Short-term Borrowings

(29.0m)22.0m299.0m(3.7b)

Long-term Borrowings

(6.0b)(25.0m)(6.0b)(1.5b)

Dividends Paid

(3.7b)(4.1b)(5.6b)(6.4b)

Cash From Financing Activities

(3.9b)(5.5b)(14.4b)18.7b

Net Change in Cash

(3.3b)4.2b(2.0b)32.6b

Interest Paid

986.0m1.1b1.2b1.8b

Income Taxes Paid

3.6b1.7b1.4b

AbbVie Ratios

USDFY, 2016

Revenue/Employee

915.6k

Debt/Equity

7.9 x

Debt/Assets

0.6 x

Financial Leverage

14.3 x

AbbVie Operating Metrics

AbbVie's Patients was reported to be 52 m in FY, 2019.
FY, 2018FY, 2019Mar, 2020

Active Clinical Trials (Oncology)

200

Countries

175 175

Exploratory Phase Products (Calico)

8

Exploratory Phase Products (Immunology)

33

Exploratory Phase Products (Neuroscience)

5

Exploratory Phase Products (Oncology)

45

Exploratory Phase Products (Other)

1

Manufacturing Facilities

14 14

Manufacturing and R&D Facilities

14

Partners

220

Patient Support Programs (US)

90

Patients

30 m52 m

Patients Included in Clinical Trials

104 k

Patients Included in Clinical Trials (US)

40 k

Patients Treated (Immunology)

1 m

Phase I Trials Products (Immunology)

2

Phase I Trials Products (Neuroscience)

3

Phase I Trials Products (Oncology)

18

Phase I Trials Products (Other)

1

Phase II Trials Products (Immunology)

6

Phase II Trials Products (Neuroscience)

2

Phase II Trials Products (Oncology)

3

Phase II Trials Products (Other)

2

Phase III Trials Products (Immunology)

11

Phase III Trials Products (Neuroscience)

1

Phase III Trials Products (Oncology)

13

Phase III Trials Products (Other)

1

Preclinical Phase Products (Calico)

2

Preclinical Phase Products (Immunology)

3

Preclinical Phase Products (Oncology)

7

Preclinical Phase Products (Other)

4

Programs

292

Research and Development Centers

8 8

Suppliers

51 k

AbbVie Sustainability Metrics

 FY, 2019

Water Withdrawn

31.70 m cubic meters

Water Consumed

4.33 m cubic meters

Waste Generated

33.40 k metric tons

Waste Disposed

9.80 k metric tons

Total Recordable Incident Rate

0.25

Lost Time Incident Rate

0.09

Hazardous Waste Generated

17.70 k metric tons

Greenhouse Gas Emissions (Scope 2, Carbon Dioxide)

250 k metric tons of carbon dioxide equivalent

Greenhouse Gas Emissions (Scope 1, Carbon Dioxide)

315 k metric tons of carbon dioxide equivalent

Energy Consumption

2.11 m MWh

Air Emissions (Carbon Dioxide)

564 k metric tons of carbon dioxide equivalent

AbbVie Human Capital

Job Roles

FY, 2019FY, 2018FY, 2017
Male (Management), percent24.6 %25.1 %25.3 %
Male (Top Managers), percent31 %30.9 %29.6 %
Female (Management), percent22.7 %22.3 %22.3 %
Female (Top Managers), percent16.4 %16.5 %18 %
Other5.2 %5.2 %4.8 %
FY, 2019FY, 2018FY, 2017
Female, percent53.3 %53.2 %53.4 %
Male, percent46.7 %46.8 %46.6 %

AbbVie Employee Rating

3.91861 votes
Culture & Values
3.7
Work/Life Balance
3.7
Senior Management
3.3
Salary & Benefits
4
Career Opportunities
3.5
Source